tetano
Editor, Senior Moderator
F1000Res
. 2022 Mar 2;11:259.
doi: 10.12688/f1000research.75869.2. eCollection 2022.
Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine
Ronald Kompier[SUP] 1 [/SUP], Pieter Neels[SUP] 2 [/SUP], Walter Beyer[SUP] 1 3 [/SUP], Tim Hardman[SUP] 3 [/SUP], Dmitry Lioznov[SUP] 4 5 [/SUP], Susanna Kharit[SUP] 6 [/SUP], Michail Kostinov[SUP] 7 8 [/SUP]
Affiliations
Abstract
A systematic review of clinical trials conducted with a low-dose inactivated influenza vaccine adjuvanted by azoximer bromide (AZB, Polyoxidonium), was performed to compare vaccine reactogenicity against non-adjuvant vaccines. We also assessed whether lower amounts of antigen per viral strain in AZB-adjuvanted vaccines affected antibody responses. A robust search strategy identified scientific publications reporting 30 clinical trials, comprising data on 11,736 participants and 86 trial arms, for inclusion in the analysis. Local reaction rates (R [SUB]lr[/SUB]) appeared to be lower in AZB-adjuvanted vaccine treatment arms versus comparator vaccine treatment arms. Post-vaccination geometric mean titres in those exposed to AZB-adjuvanted vaccine and comparator vaccine treatment arms were similar in both children and adults aged 18-60 years, implying an antigen-sparing effect by AZB. Meta‑regression analysis based on a literature search of records or reports of clinical trials featuring AZB and the inactivated subunit of influenza published between 1998-2018 was conducted online in January 2019 and updated in August 2019. This search covered trials performed between 1993 and 2016 and suggested that AZB did not contribute to vaccine reactogenicity.
Keywords: azoximer bromide; immunogenicity; influenza vaccine; meta-analysis; review; vaccine adjuvant; vaccine safety.
. 2022 Mar 2;11:259.
doi: 10.12688/f1000research.75869.2. eCollection 2022.
Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine
Ronald Kompier[SUP] 1 [/SUP], Pieter Neels[SUP] 2 [/SUP], Walter Beyer[SUP] 1 3 [/SUP], Tim Hardman[SUP] 3 [/SUP], Dmitry Lioznov[SUP] 4 5 [/SUP], Susanna Kharit[SUP] 6 [/SUP], Michail Kostinov[SUP] 7 8 [/SUP]
Affiliations
- PMID: 36176546
- PMCID: PMC9493399
- DOI: 10.12688/f1000research.75869.2
Abstract
A systematic review of clinical trials conducted with a low-dose inactivated influenza vaccine adjuvanted by azoximer bromide (AZB, Polyoxidonium), was performed to compare vaccine reactogenicity against non-adjuvant vaccines. We also assessed whether lower amounts of antigen per viral strain in AZB-adjuvanted vaccines affected antibody responses. A robust search strategy identified scientific publications reporting 30 clinical trials, comprising data on 11,736 participants and 86 trial arms, for inclusion in the analysis. Local reaction rates (R [SUB]lr[/SUB]) appeared to be lower in AZB-adjuvanted vaccine treatment arms versus comparator vaccine treatment arms. Post-vaccination geometric mean titres in those exposed to AZB-adjuvanted vaccine and comparator vaccine treatment arms were similar in both children and adults aged 18-60 years, implying an antigen-sparing effect by AZB. Meta‑regression analysis based on a literature search of records or reports of clinical trials featuring AZB and the inactivated subunit of influenza published between 1998-2018 was conducted online in January 2019 and updated in August 2019. This search covered trials performed between 1993 and 2016 and suggested that AZB did not contribute to vaccine reactogenicity.
Keywords: azoximer bromide; immunogenicity; influenza vaccine; meta-analysis; review; vaccine adjuvant; vaccine safety.